Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01879982
Other study ID # 2012-A00725-38
Secondary ID
Status Recruiting
Phase N/A
First received March 22, 2013
Last updated June 13, 2013
Start date May 2013

Study information

Verified date June 2013
Source University Hospital, Strasbourg, France
Contact n/a
Is FDA regulated No
Health authority France : ANSM
Study type Observational

Clinical Trial Summary

For the moment, the detection of a mood episode in Bipolar Disorder (BD) relies on the appearance of the first clinical signs that the clinician detect or that the patient becomes aware of and reports to the clinician. Since physiological parameters such as cardiac rhythms, respiratory rate, voice characteristics and actigraphy seem to be related to the onset of a mood episode, information collected through the combined monitoring of multiple selected physiological parameters (such as cardiac rhythms, respiratory rate, movements, voice) during wake and sleep time, using wearable user friendly systems included into garments as well as with a smartphone, may offer a new perspective in the long-term treatment of BD.


Recruitment information / eligibility

Status Recruiting
Enrollment 8
Est. completion date
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Male and female individuals aged from 18 to 65 years old (both ages included).

2. Participants meeting DSM-IV-TR criteria for bipolar disorder I or II subtypes or Participants meeting DSM-IV-TR criteria for rapid cycling BD, which is defined by a pattern of presentation accompanied by 4 or more mood episodes in a 12-month period, with a typical course of mania or hypomania followed by depression or vice versa. The episodes must be demarcated by a full or partial remission lasting at least 2 months or by a switch to a mood state of opposite polarity.

3. Female participants must agree to use efficient contraceptive methods during the study duration.

4. Participants must have signed informed consent documents indicating that they understand the purpose and procedures required for the study and are willing to participate in the study and comply with the study procedures and restrictions.

5. Patients must be affiliated with or a beneficiary of a social security system.

Exclusion Criteria:

1. Any clinically relevant acute or chronic diseases which could interfere with the participants' safety during the trial, or expose them to undue risk or which could interfere with the study objective. This last perspective includes :- Attention deficit and hyperactivity disorder (ADHD)- Borderline personality disorder (BPD)

2. Current MDD episode or manic episode, according to the DSM-IV-TR criteria

3. Current major suicidal ideation (suicidal thoughts several times a day)

4. History of recent (less than 1 year preceding inclusion) substance abuse or dependence (tobacco dependence excepted)

5. Pregnant women as determined by the patient or breast-feeding women

6. Any history of significant allergy.

7. No legal capacity or limited legal capacity or unable to give an informed consent.

8. Participants unlikely to co-operate in the study, and/or poor compliance anticipated by the investigator

9. Participants being in the exclusion period according to the French National File for participants participating in a biomedical research.

10. Total annual amount of compensation earned from participating in clinical studies exceeding 4500 Euros.

11. Patients with pacemaker, defibrillator, or any implanted electronic device (to avoid any hazard - see section 7.3.2 of the Psyche device User Manual).

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
France Service de Psychiatrie II - Hôpitaux Universitaires de Strasbourg Strasbourg Alsace

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary detect and predict mood changes in cyclothymic subjects and in rapid cycling subjects recording heart rate, respiratory rate and body activity with a wearable device ("Wearable Wellness System" or WWS), and by analysing subject's voice through a voice analysis system embedded in a smartphone. 14-week study assessment No
Secondary tolerability and acceptability of the regular use of PSYCHE multiparameter platform (WWS and the smartphone)and the feasibility and the different functionalities of the different components of the PSYCHE system in a field trial Evaluation criteria will be :
Subjective : the proportions of subjects with tolerance problems and with acceptance of future use, for the different components of the system, as assessed with the end-of-study criteria or as reported at the end of the visits on the basis of an open question ;
Objective: the proportion of missing appointments (daily and biweekly recordings) . Evaluation criteria will be :
1) Subjective : the proportions of subjects with tolerance problems and with acceptance of future use, for the different components of the system, as assessed with the end-of-study criteria or as reported at the end of the visits on the basis of an open question ; 2) Objective: the proportion of missing appointments (daily and biweekly recordings) 3) Evaluation criteria will be the estimated frequencies and types of technical and professional user problems during the study (according to a qualitative methodology)
14-week assessment study No
See also
  Status Clinical Trial Phase
Recruiting NCT04358900 - Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
Recruiting NCT05870501 - Synaptic Imaging and Network Activity in Treatment Resistant Depression N/A
Terminated NCT04058249 - Accelerated Theta Burst Stimulation for Inpatients With Bipolar Disorder N/A
Completed NCT05683431 - Using Neuroplasticity-Based Computerized Training to Improve Emotion Regulation in Bipolar Disorder (BRAINS) N/A
Recruiting NCT05934474 - Biocollection on Peripheral Inflammation
Completed NCT03822416 - Treating Smokers With Mental Illness Phase 2
Recruiting NCT05878730 - Melatonin and Response to Lithium
Not yet recruiting NCT05705063 - Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness N/A
Completed NCT02642029 - Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study N/A
Not yet recruiting NCT04168697 - Effect of Behavioral Intervention on Cannabinoid Receptors in BAD N/A
Recruiting NCT05025605 - Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder Phase 1
Completed NCT03692910 - A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode Phase 2
Active, not recruiting NCT04812379 - Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)
Not yet recruiting NCT06107764 - Cerebellar Modulation of Cognition in Psychosis N/A

External Links